J Immunother Cancer: First-line BRAF-MEKi resistance in patients with melanoma brain metastases (MBMs) is poorly treated with ipilimumab-nivolumab

Melanoma brain metastases (MBMs) are a common clinical problem
.

Research based on the US SEER database shows that about 35% of patients with advanced melanoma have brain metastases

Melanoma brain metastases (MBMs) are a common clinical problem

The study included MBM patients receiving ipilimumab-nivolumab combination therapy as first-line to third-line MBM
.

Patients receiving second-line or third-line ipilimumab-nivolumab must have melanoma with BRAF ^V600 mutation

The study included MBM patients receiving ipilimumab-nivolumab combination therapy as first-line to third-line MBM

Clinical features

Clinical features

The intracranial response rate was 75.
0% (12/16) in the first-line ipilimumab-nivolumab treatment group, and 4.
8% (1/21) in the second/third-line treatment group
.

The intracranial response rate was 75.
0% (12/16) in the first-line ipilimumab-nivolumab treatment group, and 4.
8% (1/21) in the second/third-line treatment group
.

The intracranial response rate was 75.

Intracranial response rate

Intracranial response rate

The median progression-free survival (PFS) of the first-line treatment group was 41.
6 months, and the median progression-free survival (PFS) of the second/third-line treatment group was only 1.
3 months
.

Intracranial progression-free survival (PFS) first-line patients is better than second-line/third-line patients (Mantel Cox χ 2 =21.

The median progression-free survival (PFS) of the first-line treatment group was 41.

          Intracranial PFS

Intracranial PFS

The median follow-up of the first-line and second/third-line treatment groups were 34.
5 (range: 0.
5-47.
9) and 4.
6 (range: 0.
1-46.
3) months, respectively
.

The median OS in the first-line treatment group was not reached, but the 12-month and 24-month OS rates were 76.

The median follow-up of the first-line and second/third-line treatment groups were 34.

                OS

                OS                 OS

In summary, studies have shown that after first-line BRAF-MEKi progresses in patients with melanoma brain metastases (MBMs), the second-line ipilimumab-nivolumab treatment effect is poor
.

In summary, studies have shown that after first-line BRAF-MEKi progresses in patients with melanoma brain metastases (MBMs), the second-line ipilimumab-nivolumab treatment effect is poor
.

Studies have shown that after first-line BRAF-MEKi progresses in patients with melanoma brain metastases (MBMs), the second-line ipilimumab-nivolumab treatment effect is poor

Original source:

Lau PKH, Feran B, Smith L, et al.
Melanoma brain metastases that progress on BRAF- MEK inhibitors demonstrate resistance to ipilimumab- nivolumab that is associated with the Innate PD- 1 Resistance Signature (IPRES).
Journal for ImmunoTherapy of Cancer 2021; 9:e002995.
doi:10.
1136/jitc-2021-002995

Lau PKH, Feran B, Smith L, et al.
Melanoma brain metastases that progress on BRAF- MEK inhibitors demonstrate resistance to ipilimumab- nivolumab that is associated with the Innate PD- 1 Resistance Signature (IPRES).
Journal for ImmunoTherapy of Cancer 2021; 9:e002995.
doi:10.
1136/jitc-2021-002995 leave a message here